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level [(4542.49561.08) pg/ml vs (4035.11432.65) pg/ml] in levosimendan group
24 hours after treatment. Much more improvement in dyspnea and leg swelling was
seen in levosimendan group 48 hours after treatment. Heart rate was lower in levo-
simendan group [(737.4) bpm vs (878.1) bpm] (P<0.05). However, some adverse
events occurred in levosimendan group and the total incidence of them was 14%
(7 cases with hypotention, 3 cases with headache and 2 cases with hypokalemia).
Conclusions: In patients with DHF, intravenous levosimendan increased the force of
cardiac contraction and provided rapid symptomatic relief. Levosimendan also
increased the risk of adverse events. In order to decrease the adverse events related
harm to the patients caused by levosimendan, nursing management may be of great
value during the treatment. Especially in the ﬁrst several hours of levosimendan
treatment, adverse events should be monitored carefully. Once adverse events occur or
symptoms get worse, they must be immediatly reported to the doctors to adjust the
treatment.
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Correlation of anemia and renal insufﬁciency, Neurohormonal Cytokines
In Elderly Patients With Congestive Heart Failure and effects on
ventricular remodeling
Xi Aiqi, Zhong Xin
The People’s Hospital of Qinghai Province, Xining, Qinghai, Chine
Objectives: To investigate associations among anemia and renal insufﬁciency,
Neurohormonal Cytokines Activation in Elderly patients with congestive heart failure
(CHF), and study their inﬂuence on left ventricular mass index (LVMI), mean wall
stress (MWS) and cardiac function.
Methods: 121 CHF patients were divided into the anemic group (n¼47) and the non-
anemic group (n¼74), Hb concentration, renal function, serum tumor necrosis factor-a
(TNF-a), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-1 (IL-6),
AngiotensinII (AngII) were measured. left ventricular ejection fraction (LVEF), LVMI
and MWS were measured by echocardiography.
Results: Hb concentration signiﬁcantly decreased, and the level of BUN, Cr increased
with deterioration of cardiac function in CHF patients. 38.8% of patients had anemia,
and 24% had renal insufﬁciency. the anemia and renal insufﬁciency aggravated with
decreaseing LVEF. TNF-a, sICAM-1, IL-6, AngII levels, LVMI and MWS were
higher in the anemic patient group than those in the non- anemic subject group
[(92.336.39) vs (55.6310.16) ng/L, (253.5825.96) vs (237.1833.26) ug/L,
(145.2213.53) vs (106.520.36) ug/L, (144.5364.12) vs (76.6948.49) pg/ml,
(187.78.5 ) vs (108.49.3) g/m2 and (481.125.8) vs (361.823.1) dynes103/
cm2, all P<0.01 respectively]. LVEF was signiﬁcantly decreased in the anemic patient
group compared with that in the non- anemic subject group[(33.945.23) vs
(45.358.82) P<0.01], With the increased with the severity of anemia, the levels of
TNF-a, sICAM-1, IL-6, AngII, LVMI and MWS signiﬁcantly increased; there were
positive correlation between LVMI, MWS and TNF-a, sICAM-1, IL-6, AngII levels
(P<0.01), and a negative correlation between TNF-a, sICAM-1, IL-6, AngII, LVMI,
MWS and Hb concentration (P<0.01).
Conclusions: Neurohormonal and Cytokines Activation play roles in pathophysio-
logical and pathogenetic mechanism of the severity of ventricular remodeling and
anemia, and the occurrence of anemia aggravates the change of ventricular remodeling
in CHF.
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of Cardiology, People’s Hospital of Heilongjiang Province, China, 11Department of
Cardiology, Shanghai tenth People’s Hospital, Tongji University School of Medicine,
Shanghai, China
Objectives: To evaluate whether alpha-1blocker provide additional therapeutic ben-
eﬁts than other traditional medications which are currently employed in clinical
setting, the safety and efﬁcacy of urapidil and nitroglycerin on the treatment of elderly
HF patients with hypertension and DM is investigated in a multi-center randomized
and parallel-control trial study.
Methods: 72 elderly patients were randomized into two groups with urapidil (n¼35;
M/F¼19/16) or nitroglycerin (n¼37; M/F¼20/17) treatment. Urapidil and nitroglyc-
erin are deployed with microinfusion pump with the following concentrationC184 JACC Vol 64/16/Suppl C j October 16–1respectively: 50-300 mg / min (urapidil) and 5-20 mg /kg/min (nitroglycerin). Depot
time for both of the drugs is adjusted according to individual clinical setting and lasts
for about 48-140 hours. Blood pressure (BP), heart rate (HR), metabolic panel and
cardiovascular function (NT-proBNP, EF, LVCO, LVEDV, ect.) are measured before
and after the treatment (0 hour, 24 hours, 48 hours, 72 hours and 7 days).
Results: Patients with urapidil exerted signiﬁcantly lower systolic blood pressure
(SBP) than their counterparts in the nitroglycerin group. Moreover, urapidil effectively
ameliorated the NT-proBNP level after treatment. In urapidil treatment group, EF, CI
and LEDV patients were signiﬁcantly improved compared to the patients with
nitroglycerin treatment. Both of these two drugs caused a decrease of fasting plasma
glucose (FPG). But, there was no signiﬁcant difference in FPG of patients between
urapidil- and nitroglycerin-treated groups.
Conclusions: Urapidil had better efﬁcacy than nitroglycerin on lowering and stabi-
lizing the SBP in elderly patients, attenuating the afterload and improving the cardiac
function by affecting the EF, LEDV. Like nitroglycerin, Urapidil signiﬁcantly reduced
the FPG of HF patients with DM without causing adverse effects on metabolic proﬁle
in these patients. While offering an effective way for handling BP of multifactor HF
patients who are complicated with hypertension and DM, Urapidil may provide
additional therapeutic beneﬁts to these patients. Urapidil may be another ﬁrst-line
medication in terms of its mild side effects.
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Objectives: Experimental data have suggested that Bone Mesenchymal cell (MSC )
may contribute to the healing of myocardial infarction (MI). We also have certiﬁed
that MSC is effective in treating DCM, for this reason, we treat one dialated car-
diomyopathy (DCM) patient with autologous BMCs.
Methods: One dialated cardiomyopathy (DCM) with heart failure patient were
transplanted with autologous BMCs via the coronary artery. The ejection fraction (EF)
was assessed by echocardiography before and 4, 8, 17, 21, 30, 60 days after MSC
transplantation.
Results: The MSC Transplantation had signiﬁcant sustained improvements in left
ventricular ejection fraction from before transplant (0.26), to 4, 8, 17, 21, 30, 60 days
after cell implantation (0.57, 0.52, 0.55, 0.53, 0.51, 0.45 respectively).
Conclusions: Our data demonstrate that intracoronary transplantation of autologous
BMCs improved cardiac function in DCM patient with a markedly greater improve-
ment. This approach opens a new window in the treatment of ‘no hope’ patients with
congestive heart failure.
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Analysis on the inﬂuence factors of perioperative heart failure in patients with
acute STEMI undergoing emergency PCI
Ma Jianghong, Yang Ping
China-Japan Union hospital of Ji Lin University
Objectives: To analysis the related factors of perioperative heart failure in patients
with acute STEMI undergoing emergency PCI.
Methods: The study involves 227 patients who suffered the ﬁrst acute STEMI and
accepted the treatment of emergency PCI. Record the general information of all
patients including age, gender, the history of hypertension, diabetes, high cholesterol
and smoking, the pain to balloon time, the site of myocardial infarction and the infarct
related coronary artery and whether with multi vessel disease. Record the use of
thrombus aspiration and tiroﬁban and the postoperative TIMI grade of blood ﬂow and
the. Record the speciﬁc numerical about WBC, the percentage of neutrophils, neu-
trophils to lymphocytes ratio (NLR) and mean platelet volume (MPV).Within 2 hours
after PCI again for the 12 lead ECG and record the level of ST resolution (STR)
compared with the ECG before PCI. Deﬁned the STR 50% and the STR >50%.
Record LVEF according to the cardiac ultrasound echocardiography one week after
PCI. Deﬁne LVEF 45% as heart failure group and LVEF>45% as the non heart
failure group. All the data were analyzed by statistical software SPSS17.0. The dif-
ference was statistically signiﬁcant when P<0.05.
Results: Compared with the non heart failure group, in heart failure group, the
average age (61.0812.62 vs 57.6610.78) is bigger, the average time of chest pain
to balloon (5.413.24 vs 4.412.80) is longer, the proportion of the anterior
descending branch as the infarct related coronary artery (65% vs 48%) is higher, the
proportion of the anterior wall as the site of myocardial infarction (60% vs 35%) is
higher, the proportion of using the tiroﬁban (24% vs 38%) is lower, the proportion of
postoperative TIMI grade of blood ﬂow <3 (11% vs 3%) is higher, the total number of
WBC (11.433.05 vs 10.483.02) is bigger, the percentage of neutrophils
(82.208.16 vs 73.5813.45) is higher, the NLR (8.664.13 vs 5.253.47) is
higher, and there were statistically signiﬁcant differences between the two groups
(P<0.05). Multi factor regression analysis showed that STR  50% 2 hours after PCI
and long time of chest pain to balloon are two relatively independent risk factors of
heart failure during perioperative period of emergency PCI. Linear correlation analysis
showed that the age (r¼-0.190, P¼0.004), the total number of WBC (r¼-0.134,9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
P¼0.044), percentage of neutrophils (r¼-0.355, P<0.001), NLR (r¼-0.429, P<0.001)
were negatively correlated with LVEF value.
Conclusions: (1) STR 50% and long time of chest pain to balloon are independent
risk factors of perioperative heart failure in patients with acute STEMI undergoing
emergency PCI. (2) Using of tiroﬁban has good protective effect on perioperative
cardiac function in patients with acute STEMI undergoing emergency PCI. (3) The
increased NLR is a risk factor of perioperative heart failure in patients with acute
STEMI undergoing emergency PCI. And NLR has good correlation with perioperative
left ventricular ejection fraction.
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The feasibility study on the biventricular pacing both dynamic combined of
atrioventricular nodal conduction to improve the treatment of heart failure
Qin Zuoan, Li Ruijie, Guo Tao
First Afﬁliated Hospital of Kunming Medical College
Objectives: Assess the biventricular pacing dynamic combined of atrioventricular
nodal conduction function and improve the efﬁcacy of the cardiac pacing.
Methods: From 2012 January to 2013 September, we have selected the 30 patients
who are admitted to the First Afﬁliated Hospital of Kunming Medical University and
accorded with the CRT IA indication of the 2013 ACCF/AHA/HRS guidelines. 30
patients were randomly divided into dynamic group and non-dynamic control group,
with 15 cases in each group. all patients completed immediately, 3 month and 6 month
followed of take the ECG, 24 h Holter, echocardiography, NYHA, 6 MWT, MLHF
and so on. We analyze data by using SPSS 17 statistical software package, P<0.05.
Results: (1) The two group immediate width of QRS after optimized was more
narrow than the traditional AVd optimization method, in the dynamic group
(138.3321.83 ms and 169.13 20.31 ms, P<0.001); in the control group
(133.3313.58 ms and 174.3315.69 ms, P<0.001). (2) Compared the ﬁrst opti-
mized immediately, both Ts-SD12 and AVTI values improved in after 6 months. In
the dynamic balance group (Ts-SD12 117.2042.78 ms and 147.4037.70 ms;
AVTI 20.494.30 cm and 18.252.14 cm, P<0.05); In the control group (Ts-
SD12 116.8036.26 ms and 154.2729.71 ms; AVTI 19.092.05 cm and
17.362.53 cm, P<0.05).The comparison of 6 months follow-up measurement
value, difference in two group had no signiﬁcant (117.2042.78 ms and
116.8036.26 ms, P¼0.937; 20.494.30 cm and 19.092.05 cm, P¼0.245). (3)
CRT preoperatively, after immediately optimized, with 3 months, 6 months follow-
up detection of ultrasonic index comparison, the difference of inter-group improved
(P<0.05), but the difference between the groups had no signiﬁcant (P>0.05). (4)
Compared with the ﬁrst optimized immediately, NYNA / 6WMT / MLHF of all
patients with 6 months in two groups were improved.NYNA (the dynamic group
1.60.5 and the control group 2.70.6;1.50.5 and 2.60.6, P<0.05); 6MWT
(the dynamic group 379.6728.75 m and 337 25.13 m; the control group
38130.66 m and 346.4731.98 m, P<0.001); MLHF (the dynamic group 28
10.73 and 36.87 16.44; the control group 25.3315.61 and 36.6720.91,
P<0.05).The difference of the indexes between the two groups with follow-up of
6 months was no signiﬁcant (NYNA1.60.5 and 1.50.5; 6MWT 379.6728.75 m
and 38130.66 m; MLHF 28.0010.73 and 25.3315.61, P>0.05). (5) Compared
with the ﬁrst optimization after 24 h ECG, dynamic group with the best “true fusion
QRS wave” is higher than the control group (80.67% and 52.67%, P¼0.001);
“ventricular false convergence” between the two groups accounted for the proportion
of total cardiac was lower than 2%, and there was no signiﬁcant (1.28% and 1.74%,
P¼0.427).
Conclusions: (1) With sinus rhythm in patients with CHF were treated by CRT and
both the “atrioventricular node priority” and allowed 100% “true fusion” and “false
fusion” biventricular pacing capture classic mode. This type lead to narrower QRS
wave. (2) Biventricular pacing both atrioventricular nodal intrinsic conduction is
simple, noninvasive safety, The patients implanted CRT with narrower QRS wave can
improve heart function and quality of life and the response rate. There is an increasing
trend to beneﬁt to the patients with implementation of biventricular pacing “atrio-
ventricular node priority”. (3) Dynamic balance of atrioventricular node intrinsic
conduction “3 Chamber&4 site Pacing” mode, improve biventricular pacing stimulus
and AV node conduction “really inherent fusion QRS wave”.
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Study on the Effect of Luo Feng Ning NO.2 to the Quality of Life of patients with
Cardiorenal Syndrome
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Objectives: To investigate the effect of Luo Feng Ning NO.2 to the quality of life of
patients with cardiorenal syndrome.
Methods: 46 patients with cardiorenal syndrome patients were randomly divided into
the Luo Feng Ning NO.2 group (n¼12), the expelling wind drug group (n¼10), the
remove expelling wind drug group (n¼9), and the western medicine group (n¼15).
Minnesota Living With Heart Failure Questionnaire, 6-minute walk test, the standard
of curative effect evaluation, and the typical symptom quantitative score of heart and
kidney were used as the, index for appraising quality of life before and after 3 months
treatment, respectively.
Results: After 3 months treatment, MLHFQ score of the Luo Feng Ning NO.2 group,
the expelling wind drug group, the remove expelling wind drug group was statisticallyJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/Csigniﬁcant (P<0.05) compared with before treatment, while MLHFQ score of the
western medicine group tends to aggravate. Comparison among groups, the score of
the Luo Feng Ning NO.2 group was the lowest by the obvious improvement and the
difference was statistically signiﬁcant (P<0.05). Comparison before and after
3 months treatment among in the four groups, 6-minute walking distance were all
prolonged, the difference was statistically signiﬁcant (P<0.05). But the differences
were not statistically signiﬁcant (P>0.05) among the four groups. After the treatment,
the total efﬁciency of four groups from large to small order: the Luo Feng Ning NO.2
group, the expelling wind drug group, the remove expelling wind drug group, western
medicine group. After 3 months, the typical symptom score of four groups have no
statistically signiﬁcance (P>0.05).That is not obvious symptoms improvement before
and after treatment. But from the view of x s, the typical symptom quantitative score
of the Luo Feng Ning NO.2group, wind drug group, remove wind drug group all have
increased and the Luo Feng Ning NO.2 group was obviously lower, while the western
medicine group score changed little or increased.
Conclusions: Luo Feng Ning NO.2 can improve the quality of life on cardiorenal
syndrome patients.
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Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary
hypertension secondary to chronic systolic heart failure
Wu Xiaojing, Huang Lan
Cardiovascular Department of Xinqiao Hospital, Third Military Medical University
Objectives: Increased indiscriminate use of pulmonary artery hypertension targeted
drugs has been observed in patients with pulmonary hypertension (PH) secondary to
heart failure. We performed a meta-analysis to evaluate the chronic effects of using
phosphodiesterase 5 (PDE5) inhibitors to treat patients with PH secondary to chronic
systolic heart failure.
Methods: PubMed, EMBASE, and the Cochrane Library were searched through
October 2013 for randomized controlled trials (RCTs) assessing PDE5 inhibitor
treatments in PH patients secondary to chronic heart failure. Six RCTs involving 206
chronic systolic heart failure patients with PH complications were included.
Results: Sildenaﬁl was used in all trials. Sildenaﬁl treatment resulted in fewer hospital
admissions compared with the placebo treatment (3.15% versus 12.20%; risk ratio,
0.29; 95% conﬁdence interval, 0.11-0.77). Various hemodynamic parameters were
improved with additional sildenaﬁl treatment, including reduced mean pulmonary
artery pressure (weighted mean differences, [WMD], -5.71 mmHg, P<0.05), and
pulmonary vascular resistance (WMD, -81.5 dynes/cm-5, P<0.00001), increased left
ventricular ejection fraction (WMD, 3.95%, P<0.001), and unchanged heart rate and
blood pressure. The exercise capacity improved (Oxygen consumption at peak exer-
cise, WMD, 3.20 ml/min-1/kg-1, P<0.00001; Ventilation to CO2 production slope,
WMD, -5.89, P<0.00001), and the clinical symptoms were relieved based on the
breathlessness (WMD, 7.72, P<0.00001), fatigue (WMD, 2.28, P<0.05), and
emotional functioning (WMD, 5.92, P<0.00001) scores.
Conclusions: Additional sildenaﬁl treatment is a potential therapeutic method to
improve pulmonary exercise capacity and quality of life by ameliorating PH in
patients with chronic systolic heart failure.
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Research on Diagnostic Criteria of Congestive Heart Failure with Qi-yin
Deﬁciency Syndrome and Yang-deﬁciency-water-overﬂowing Syndrome Based
on Clinical epidemiological Survey
Li Xiaoqian, Hejiancheng, Cao Xuebing, He Jiancheng
Shanghai University of T.C.M
Objectives: To discuss the clinical rules of TCM four diagnostic information and
relevant indicators in qi-yin-deﬁciency syndrome and yang-deﬁciency-water-
overﬂowing syndrome of congestive heart failure, and consummate diagnosis criteria
of the two syndromes.
Methods: 750 CHF cases from multicenter (from Dec, 2012 to Dec, 2013) were
collected by applying TCM syndrome scale of congestive heart failure. Related items,
primary and secondary symptoms of syndromes were screened by the method of
logistic regression. The assignment of items related to the syndromes was by means of
conditional probability conversion method. The threshold values in clinic diagnosis of
qi-yin-deﬁciency syndrome and yang-deﬁcieny-water-overﬂowing syndrome got
determined combined with ROC curve. Reference range of BNP also got described by
the mean value and median.
Results: Based on retrospective analysis of clinical cases (1694 cases), applying rank
sum test, Spearman rank correlation analysis, clustering and factor analysis, results
indicated: qi-yin-deﬁciency syndrome is one of the common patterns of CHF, and
yang-deﬁciency-water-overﬂowing syndrome can be mostly seen in the later period.
The major deﬁning characteristics of qi-yin-deﬁciency with blood-stasis syndrome are
thirst, cyanotic lips, sweating, frequent nigh urination, teeth-printed or cyanotic
tongue, uneven or irregular pulse. The minor characteristics are loose stool, headache,
and bulgy tongue with slip or little fur, slow, weak, or ﬂoating pulse. The major
characteristic of yang-deﬁciency-water-overﬂowing syndrome are cough, expectora-
tion, insomnia, bad appetite, difﬁcult urination, edema of lower limbs, greasy fur and
string pulse. The minor one is fatigue. The diagnosis criteria of CHF qi-yin-deﬁciency
syndrome is total score of related items is equal or greater than 68 points (sensitivity:
95%, speciﬁcity: 82.4%), and the reference range of BNP is from 93.57 to 182.59
pg/ml. The diagnosis criteria of yang-deﬁciency-water-overﬂowing syndrome is totalardiovascular Disease Clinical Research C185
